Abstract:Abstract Background Cancer immunotherapy targeting immune checkpoints has shown promising clinical anti-tumor efficacy over the past decades. Monoclonal antibodies against PD-1 or PD-L1 have demonstrated clinical efficacy in a wide spectrum of cancer types. Despite the clinical success of therapies using immune checkpoint inhibitors (ICI), only a subset of patients shows long-lasting tumor remission, while resistance and toxicities to these agents remain to be addressed. This supports the need to explore alternative immunotherapeutic approaches or additional therapies for synergistic combinations to augment the anti-tumor efficacy for cancer patients receiving ICI therapies. Methods As an active immunotherapy approach, we developed a blend of four novel synthetic peptide vaccines each containing one PD-L1 T-cell epitope with individual covalent conjugation of the carrier protein, keyhole limpet haemocyanin (KLH), which is to break immune tolerance towards self-molecules. The four PD-L1 epitopes range from 30 to 40 amino acids in length, which target different domains of mouse PD-L1 protein. The PD-L1 peptides were synthesized using the technique of solid-phase peptide synthesis and purified by high performance liquid chromatography. All naked peptides were conjugated to KLH protein by thiol-maleimide reaction, followed by dialysis for purification. The peptide vaccines were formulated with a Toll-like receptor 9 agonist CpG ODN 1826 and aluminum hydroxide gel for animal immunization. Results These synthetic long PD-L1 peptide vaccines are highly immunogenic in a syngeneic BALB/c mouse model for a cell-mediated immune response when admixed and formulated with adjuvants. The vaccine composition is well tolerated by the mice with no evidence of toxicity and autoimmunity. In vivo administration of the vaccine formulation can elicit a positive PD-L1-specific T cell response in splenocytes with an IFN-γ ELISPOT assay. Moreover, in vivo vaccination of these PD-L1 peptide vaccines in a CT26 syngeneic mouse preventive colorectal cancer model exhibits a potent anti-tumor activity, with a 54% tumor growth inhibition (p<0.001) in tumor volume compared to that of the adjuvant-control group at the end of the study. Conclusions Taken together, our data demonstrate a proof-of-concept that T cell-based PD-L1 peptide vaccines are a promising therapeutic strategy for inducing anti-tumor immunity to combat cancers. Citation Format: Kenneth Nansheng Lin, Melvin Toh. A novel synthetic long peptide vaccine composition targeting multiple PD-L1 T-cell epitopes exhibits anti-tumor efficacy in a syngeneic mouse colorectal cancer model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4106.

Antitumor Potential of A Synthetic Interferon-Alpha/Plgf-2 Positive Charge Peptide Hybrid Molecule in Pancreatic Cancer Cells

The Antitumor Activity Of Synthetic Interferon-Alpha In Pancreatic Cancer Cells.

A Placental Growth Factor-Positively Charged Peptide Potentiates the Antitumor Activity of Interferon-Gamma in Human Brain Glioblastoma U87 Cells.

Synthetic small peptides acting on B7H1 enhance apoptosis in pancreatic cancer cells.

A Novel Engineered Interferon-Α Hybrid Molecule Increases Anticancer Efficacy of Doxorubicin in Breast Cancer Chemotherapy.

A New Fusion Peptide Targeting Pancreatic Cancer and Inhibiting Tumor Growth.

Combination Doxorubicin And Interferon-Alpha Therapy Stimulates Immunogenicity Of Murine Pancreatic Cancer Panc02 Cells Via Up-Regulation Of Nkg2d Ligands And Mhc Class I

Interferon-α in Combination with Chemotherapy Has Potent Antiangiogenic Properties in an Orthotopic Mouse Model for Pancreatic Adenocarcinoma

Pancreatic Carcinoma-Specific Immunotherapy Using Synthesised Alpha-Galactosyl Epitope-Activated Immune Responders: Findings from a Pilot Study

Inhibition of DEF‐p65 Interactions as a Potential Avenue to Suppress Tumor Growth in Pancreatic Cancer

Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.

Design and Evaluation of Α-Helix-based Peptide Inhibitors for Blocking PD-1/PD-L1 Interaction.

High-yield Expression, Purification and Characterization of Tumor-Targeted IFN-α2a

Adenovirus‐mediated Interferon‐γ Gene Therapy Induced Human Pancreatic Carcinoma Capan‐2 Cell Apoptosis in Vitro and in Vivo

Peptide Tyrosine-Tyrosine Combined with Its Receptors Exhibits an Anti-Cancer Potential in Pancreatic Cancer Miapaca-2 Cell

Abstract 4106: A novel synthetic long peptide vaccine composition targeting multiple PD-L1 T-cell epitopes exhibits anti-tumor efficacy in a syngeneic mouse colorectal cancer model

Enzyme-Activatable Interferon–Poly(α-amino Acid) Conjugates for Tumor Microenvironment Potentiation

PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapy

Small peptides elicit anti-tumor effects in CT26 model through blocking PD-L1/PD-1 (TUM2P.900)

Anti-tumor efficacy and pre-clinical immunogenicity of IFNα2a-NGR.

Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FAK inhibitors for the potential treatment of pancreatic cancer